-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
More Than a Partnership: How Oncogene-Driven Patient Groups Are Mobilizing the Global Community to Drive Research
It has been just over a year since we reported how oncogene-driven patient advocacy groups are disrupting the research paradigm in lung cancer.1 We have indeed come a long way since the discovery of the first EGFR mutation in lung cancer in 2004.2 ,3 Even amid the challenges of the global COVID-19 pandemic, the lung…
-
Awareness-raising Bike Ride in The Netherlands Connected Hospitals, Patients
Patients and supporters cycled nearly 1,150 kilometers through The Netherlands on May 21, 2021 in a “White Ribbon Tour” to raise awareness for lung cancer. The grassroots event was organized by Niels Harthoorn, age 22, an industrial engineering and management student at the University of Twente, and a patient with lung cancer. For the ride,…
-
Broad Molecular Testing in Lung Cancer: The Struggle to Translate Recommendations to Clinical Practice
By Kara Nyberg, PhD Posted: June 24, 2020 Over the past decade, lung cancer has emerged as a shining example of how precision medicine can dramatically improve patient outcomes. Up to 85% of patients with lung cancer harbor potentially actionable driver mutations, and matching targeted therapy to druggable alterations in the first-line setting prolongs survival…
-
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
By Kara Nyberg, PhD Posted: June 24, 2020 An exploratory analysis of circulating free DNA (cfDNA) shows that lorlatinib confers potent antitumor activity in pretreated patients with ALK-positive NSCLC regardless of EML4-ALK variant type and across a variety of ALK resistance mutations. The duration of response also appears consistent across all ALK fusion subtypes. “Our…
-
Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade
By Kara Nyberg, PhD Posted: April 16, 2020 After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life into the beleaguered field of lung cancer research. Treatment progress gained momentum and finally reached a tipping point in the mid-2010s, with the number of advances over the last…
-
Lung Cancer Leading the Charge for Tumor-Agnostic Targeted Therapies
By Robert C. Doebele, MD, PhD Posted: December 11, 2019 Dr. Robert C. Doebele Early in the drug development of targeted therapies, specific oncogene mutations were often associated with a single disease: HER2 gene amplification with breast cancer, BCR-ABL fusions with chronic myelogenous leukemia, EGFR mutations with lung cancer, and BRAF mutations with melanoma. Thus,…